high prevalence of skin diseases is driving the Non-Cancerous Skin Diseases Therapeutics Market

Latest News:- Non-Cancerous Skin Diseases Therapeutics Market: Psoriasis is expected to lead the Therapy Area segment during 2024-2028

Technavio analyzes that the Non-Cancerous Skin Diseases Therapeutics Market is expected to grow at a CAGR of 9.88% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 25.22 billion.There are various factors that contribute to the growth of the market. The non-cancerous skin diseases therapeutics market is witnessing significant growth due to the high prevalence of various skin conditions, such as psoriasis, eczema, and atopic dermatitis. These diseases affect millions of people worldwide, leading to a substantial demand for effective treatments. The market is driven by advancements in biotechnology and pharmaceuticals, resulting in the development of novel therapies and delivery systems. Additionally, increasing awareness and early diagnosis are expected to further fuel market growth.

The non-cancerous skin disease, psoriasis, affects over 125 million individuals worldwide, making it a significant global health concern. This chronic and non-communicable condition accelerates the life cycle of skin cells, resulting in excess skin production that manifests as scales and red patches on the skin's surface. The root cause of psoriasis lies in an immune system abnormality, potentially leading to mental health issues and comorbidities such as cardiovascular diseases and diabetes. Plaque psoriasis, the most prevalent type, accounts for 80-90% of diagnosed cases. In the therapeutic landscape, cellular therapies like Amtagvi (lifileucel) and extracellular vesicles show promise. Genetic mutations play a role in psoriasis development, and environmental factors, such as ozone layer depletion, may exacerbate symptoms. Branded drugs remain crucial in managing this condition, providing relief to those affected. 

Know which region is leading the market growth by requesting a sample report

Non-Cancerous Skin Diseases Therapeutics Market Segmentation

• Therapy Area
  • Psoriasis
  • Eczema
  • Acne vulgaris
  • Others
• Route Of Administration
  • Injectable
  • Oral
  • Topical
• Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

Top Performing Companies

As per our research findings, here are some of the key competitors that are leading the industry

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Galderma SA
• GlaxoSmithKline Plc
• Incyte Corp.
• LEO Pharma AS
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• UCB SA
• Viatris Inc.
• XBiotech Inc.

Find out what is trending in the market by accessing the free PDF report

Research Analysis Overview

The Non-Cancerous Skin Diseases Therapeutics Market encompasses treatments for various conditions, excluding skin cancer. Notable forms of cancer, such as melanoma and uveal melanoma (mUM), are distinguished from this market. Key therapeutic options include KIMMTRAK (tebentafusp) and KEYTRUDA for melanoma, with the latter also used for some chronic diseases in immunocompromised patients. Immunotherapy, such as lymphocyte activation gene 3 assay, targeted therapies like immunotherapy with pembrolizumab and nivolumab, chemotherapy, cellular therapy, and surgery are utilized for metastatic melanoma, desmoplastic melanoma, and other skin diseases. Novel immunotherapies and combination therapies continue to emerge in the melanoma therapeutics landscape.

Market Research Overview

The Non-Cancerous Skin Diseases Therapeutics Market, as identified by Technavio, is a segment of the expansive Global Pharmaceuticals Market within the broader Healthcare Industry. This market encompasses entities involved in Research and Development (R&D) or manufacturing of various pharmaceutical offerings, including non-generic and generic drugs, as well as veterinary medicines. The Global Pharmaceuticals Market's size is determined by Technavio through the consolidated revenue generated by the manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Key growth drivers for the Global Pharmaceuticals Market include the increasing global population aging, with the number of individuals above 60 years projected to rise significantly. This demographic shift will lead to a greater demand for healthcare solutions, including those for non-cancerous skin diseases, particularly among the immunocompromised population and those requiring intensive care.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Reasons to Consider Purchasing Technavio Market Research Report

• Current Market Insights: Our reports offer valuable information on the latest market intelligence, competitor strategies, trends, industry changes, customer preferences, and forecasted market opportunities to aid in informed business decisions.


• Extensive Experience: With over 20 years in market research, Technavio is a trusted name, having published more than 21,000 reports across various industries and regions.


• High ROI Through In-Depth Research: Technavio specializes in tailored market research reports to meet specific business needs, exploring particular markets, product segments, and demographics. We are also recognized for delivering significant returns on investment through our comprehensive data collection at affordable prices.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/